Reproductive Health

Stem Cell Therapy for Female Infertility & Ovarian Insufficiency

How mesenchymal stem cell therapy is being explored for premature ovarian insufficiency, diminished ovarian reserve, thin endometrium, and recurrent IVF failure — and what realistic expectations look like in 2026.

14 min read

Educational

Ultimo aggiornamento: 5 febbraio 2026

Revisionato medicalmente da Team Medico SCL

Summarize with AI:

The Female Infertility Landscape in 2026

Female infertility affects an estimated 1 in 6 couples globally, and the patient population has shifted significantly with rising maternal age at first conception. Conditions that disproportionately affect older patients — diminished ovarian reserve, premature ovarian insufficiency, thin endometrium, recurrent implantation failure — have become more common in fertility practice. Modern reproductive medicine offers powerful tools (ovarian stimulation, IVF, ICSI, PGT-A, donor oocytes), but for some patients these tools reach their limits.

Premature ovarian insufficiency (POI) — loss of ovarian function before age 40 — affects approximately 1% of women, with devastating implications for both fertility and long-term health. Diminished ovarian reserve, where AMH is low and antral follicle count is reduced for age, is increasingly common. Thin endometrium that does not adequately develop for embryo implantation affects a smaller but significant subgroup of IVF patients. Recurrent implantation failure after multiple high-quality embryo transfers remains one of the most frustrating clinical challenges.

Mesenchymal stem cell therapy is being explored as an emerging adjunctive option for selected patients with these conditions. The biological rationale — anti-inflammatory action, growth factor delivery, microvascular support, and modulation of the local tissue environment — is plausible. The 2026 evidence base is growing through Phase 1 and Phase 2 trials, and the treatment is being offered in selected international fertility centres in conjunction with conventional reproductive care.

How MSCs Address Reproductive Biology

MSCs intervene in mechanisms relevant to ovarian function, endometrial receptivity, and embryo implantation.

Ovarian Microenvironment

MSC-secreted growth factors and anti-inflammatory cytokines may improve the ovarian microenvironment supporting follicular development.

Granulosa Cell Support

MSCs may support granulosa cell function and reduce apoptotic loss of follicles, particularly relevant in diminished ovarian reserve.

Endometrial Repair

Direct MSC injection into the uterine cavity has shown encouraging signals in published series for thin endometrium and Asherman's syndrome.

Implantation Environment

MSCs reduce inflammatory cytokines that may interfere with embryo implantation, particularly in recurrent implantation failure.

Microvascular Support

Both ovarian and endometrial function depend on microvascular health. MSC-secreted angiogenic factors support tissue vascularisation.

HPA Axis Modulation

Reducing systemic inflammation may indirectly support hypothalamic-pituitary-ovarian axis function in selected patients.

Reproductive Conditions That May Respond

Conditions with the most supporting evidence for MSC therapy in 2026 reproductive medicine.

Premature ovarian insufficiency (POI) with documented AMH and FSH abnormalities

Diminished ovarian reserve (low AMH, reduced antral follicle count for age)

Thin endometrium not responding to standard hormonal preparation

Asherman's syndrome with intrauterine adhesions and endometrial damage

Recurrent implantation failure (RIF) after 3+ high-quality embryo transfers

Recurrent pregnancy loss with possible inflammatory or implantation component

Selected cases of polycystic ovary syndrome with refractory metabolic component

Post-chemotherapy ovarian damage in cancer survivors

What the Clinical Evidence Shows

Clinical evidence for MSC therapy in female infertility is most extensive for thin endometrium and Asherman's syndrome, where direct intrauterine MSC delivery has shown meaningful improvements in endometrial thickness, pregnancy rates, and live births in published series. For premature ovarian insufficiency and diminished ovarian reserve, the evidence is earlier-stage but growing — multiple Phase 1/2 trials of intravenous MSC therapy and direct intraovarian injection have shown improvements in AMH, antral follicle count, hormone profile, and in some cases successful pregnancy.

For recurrent implantation failure, the evidence is more limited but supportive in selected cases, particularly where inflammatory or immunological factors are believed to contribute to implantation failure. The treatment effect typically develops over 1-3 menstrual cycles after treatment, and most successful pregnancies in published series have occurred 3-6 months after MSC therapy.

The 2026 honest summary is that MSC therapy may meaningfully improve fertility outcomes in selected patients with specific reproductive challenges, but it is not a universal solution. Patients with severe established ovarian failure, advanced age (over 45), or other significant prognostic factors may have limited benefit. The treatment should be approached as one part of a comprehensive reproductive medicine plan, not as a standalone intervention.

Treatment Protocol

A typical 2026 protocol uses allogeneic Wharton's jelly MSCs delivered through one or more routes depending on the indication. For diminished ovarian reserve and POI, intravenous infusion is the standard, sometimes combined with direct intraovarian injection performed under transvaginal ultrasound guidance. For thin endometrium and Asherman's syndrome, intrauterine MSC delivery via hysteroscopy or via cannula is typically used. Cell doses are individualised based on the indication.

Pre-treatment evaluation includes detailed reproductive assessment (AMH, FSH, estradiol, antral follicle count, uterine cavity assessment, recent IVF history if applicable), general health screening, and discussion of timing relative to any planned IVF cycle. The treatment plan is coordinated with the patient's reproductive endocrinologist whenever possible. Most patients pursue MSC therapy 2-4 months before a planned next IVF cycle to allow time for the treatment effect to develop.

The procedures themselves are well tolerated. IV infusion is straightforward outpatient care. Intraovarian injection is performed under sedation similar to oocyte retrieval. Intrauterine delivery is performed in office or operating room setting. Most patients return home within a week of arrival. Follow-up tracks reproductive markers, response to subsequent fertility treatment, and pregnancy outcomes.

Integration with IVF and Reproductive Medicine

MSC therapy works alongside, not instead of, established reproductive medicine.

Reproductive Endocrinologist

Your fertility specialist should remain central to your care. MSC therapy is adjunctive, designed to improve the substrate that IVF and other treatments work with.

Continue IVF Planning

MSC therapy is generally most useful 2-4 months before a planned IVF cycle, allowing time for tissue effects to develop.

Realistic Timing

Effects on ovarian function develop gradually over 2-3 months. Endometrial effects may be visible within 1-2 cycles. Fertility outcomes are tracked over 6-12 months.

Donor Oocyte Conversation

For some patients with very advanced ovarian failure, donor oocytes remain the highest-success-rate path. We are honest when this is the more realistic option.

Outcome Tracking

AMH, antral follicle count, response to ovarian stimulation, embryo quality, and pregnancy rates allow assessment of treatment effect.

Pregnancy Safety

MSC therapy is given before conception, not during pregnancy. Treatment during pregnancy is contraindicated as safety in pregnancy is not established.

Suitability Considerations

Honest patient selection is essential.

Confirmed reproductive diagnosis from a qualified reproductive endocrinologist

Documented inadequate response to conventional reproductive treatment

Realistic age range — generally under 45, with case-by-case evaluation

No active malignancy or contraindication to MSC therapy

Realistic expectations: improved chance of conception, not guaranteed pregnancy

Willing to coordinate with home reproductive medicine team

Healthy enough to undergo treatment protocol

Honest discussion of when donor oocytes or alternative paths may be more realistic

Frequently Asked Questions

In some published cases, yes — small numbers of patients with POI have achieved natural pregnancy after MSC therapy. However, this is not the typical outcome. Most patients with POI who become pregnant after MSC therapy do so in the context of subsequent assisted reproduction (IVF) with their own oocytes. For patients with severe established POI and very low ovarian reserve, donor oocytes remain the most reliable path to pregnancy, and we are honest with patients when this is realistic option.

The optimal timing depends on the indication. For ovarian reserve issues, most experienced centres recommend 2-3 months after treatment before starting an IVF cycle, allowing time for the cellular and biochemical effects to develop. For endometrial issues, 1-2 menstrual cycles typically allow assessment of endometrial response before transferring an embryo. The exact timing should be coordinated with your reproductive endocrinologist.

Most fertility medications can be coordinated around MSC therapy, although the specific timing should be discussed with both your fertility specialist and the treating clinic. Some patients pause hormonal stimulation around the time of MSC infusion to allow a clean assessment of treatment effect; others continue. The decision should be individual and based on the specific situation.

When performed by an experienced reproductive specialist under transvaginal ultrasound guidance, intraovarian injection is a well-tolerated procedure similar in technique to oocyte retrieval. Complications such as bleeding or infection are uncommon. The main consideration is that the procedure should be performed only by clinicians with appropriate reproductive medicine expertise — it is not a procedure to be done by general regenerative medicine practitioners.

MSC therapy is generally not associated with adverse effects on IVF cycles when properly timed. In fact, the goal is often to improve ovarian response or endometrial receptivity for the subsequent IVF cycle. Most patients pursue MSC therapy 2-4 months before a planned IVF cycle to maximise the potential benefit. Coordination with your fertility specialist on timing is essential.

We offer protocols including IV infusion, intraovarian injection, and intrauterine MSC delivery depending on the indication, performed in coordination with our fertility-medicine partners. Pre-arrival case review, in-house procedures, and structured follow-up coordinated with your home fertility specialist are included. We are honest when alternative paths (donor oocytes, etc.) may be more realistic for the specific case. Request a free consultation for an individualised assessment.

Continue Your Research

Discuss Your Reproductive Case with a Specialist

Our team will review your reproductive history in coordination with your fertility specialist and tell you honestly whether MSC therapy is likely to improve your chance of pregnancy.

Coordinamento Internazionale dei Pazienti

StemCell Longevita opera come piattaforma di coordinamento internazionale dei pazienti. Mettiamo in contatto i pazienti con istituzioni mediche autorizzate che offrono applicazioni di medicina rigenerativa dopo valutazione medica e nel rispetto dei quadri normativi applicabili. Tutte le decisioni e le procedure mediche sono condotte esclusivamente da professionisti sanitari autorizzati. StemCell Longevita non fornisce direttamente trattamenti medici.

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.

The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.

L'inclusione di pubblicazioni scientifiche su questo sito non implica approvazione normativa o risultati clinici garantiti. Alcune applicazioni possono essere considerate sperimentali a seconda dell'indicazione e della giurisdizione.

Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.